Nurullah İlhan,MD· @drnurullahilhan · X·· 17 小时前评分70
正文 · 机器翻译
FOURLIGHT-1：接受CDK4/6i治疗后的HR+/HER2−乳腺癌。
Atirmociclib + fulvestrant达到了II期PFS终点：
9.4个月 vs 6.6个月；HR 0.60。
对照组：fulvestrant或everolimus/exemestane。
未显示相较后者的单独优效性。
#FOURLIGHT1 #ESMO2026 #BCSM
8 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org来源：Nurullah İlhan,MD · x.com